| Literature DB >> 25614858 |
Parisa Badiee1, Ahmad Ali Amirghofran2, Mohammad Ghazi Nour2, Masih Shafa2, Mohammad Hassan Nemati2.
Abstract
BACKGROUND: Fungal endocarditis, the most severe form of infective endocarditis, is characterized by excessive mortality and morbidity.Entities:
Keywords: Aspergillus; Candida; Endocarditis; Fungus Susceptibility
Year: 2014 PMID: 25614858 PMCID: PMC4302502
Source DB: PubMed Journal: Int Cardiovasc Res J ISSN: 2251-9130
Characteristics of Fungal Endocarditis Patients with the MICs of the Isolates (µ/mL)
| MIC | µ/mL | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No | Sex/Age | Etiologic | Amphotericin | Ketoconazole | Itraconnazole | Fluconazole | Posacoazole | Voriconazole | Caspofungin |
|
| F/27 |
| 0.125 | 32 | 1.5 | 0.047 | 0.064 | 0.047 | |
|
| M/17 |
| 2.0 | 1.5 | 0.032 | 0.25 | 0.19 | 0.19 | |
|
| M/4 |
| 4.0 | 1.0 | 0.032 | 0.125 | 0.19 | 0.047 | |
|
| M/50 |
| 2.0 | 3.0 | 0.5 | 0.38 | 0.75 | 0.016 | |
|
| M/31 |
| 0.5 | 1.5 | 0.5 | 32.0 | 0.094 | 0.125 | 0.032 |
|
| F/67 |
| 0.064 | 0.125 | 1.5 | 0.016 | 0.023 | 0.19 | |
|
| M/19 |
| 0.25 | 0.75 | 0.125 | 0.5 | 0.5 | 0.016 | |
|
| M/42 |
| 2.0 | 16.0 | 3.0 | 0.38 | 0.064 | 0.023 | |
|
| M/64 |
| 0.5 | 1.5 | 0.125 | 0.75 | 0.125 | 0.032 | |
|
| F/35 |
| 0.5 | 2.0 | 2.0 | 0.19 | 0.19 | 0.064 | |
|
| M/21 |
| 0.25 | 1.0 | 1.0 | 16.0 | 0.064 | 0.64 | 0.016 |
Abbreviations: A, Aspergillus; C, Candida
Characteristics of Fungal Endocarditis Patients
| No | Onset after Surgery | PCR in Blood | PCR in Tissue | Antifungal Therapy | Predisposing Risk Factors | Outcome |
|---|---|---|---|---|---|---|
|
| 4 month | + | + | Amphotericin B | Previous surgery (4 times) | Clinically well after 12 month return with recurrent endocarditis |
|
| 4 years | + | + | Voriconazole | Previous surgery (3 times) | Clinically well after 12 month |
|
| 12 month | + | + | Voriconazole | Permanent pacemaker | 12 month Clinically well after |
|
| Not available | - | + | Amphotericin B | No predisposing risk factors | Clinically well after 12 month |
|
| Not available | + | + | Amphotericin B | IV drug abuser since 12 years ago. | Clinically well after 12 month |
|
| 2 month | + | + | Amphotericin B | Prostetic valve replacement | Clinically well after 12 month |
|
| 5 month | + | + | Voriconazole | Previous surgery (1 times) | Clinically well after recurrent |
|
| 4 month | + | + | Any treatment | Previous surgery (1 times) | Died before using the treatment |
|
| 6 month | + | + | Voriconazole | Previous surgery (1 times) | Clinically well after 12 month |
|
| 2 month | + | + | Any treatment | Previous surgery (2 times) | Died before using the treatment |
|
| Not available | + | + | Amphotericin B | IV drug abuser | Clinically well after 12 month |